Renal Cell Carcinoma
From the Journals
Is cancer immunotherapy more effective in men than women?
Cancer immunotherapy with checkpoint inhibitors appears to achieve greater mortality reductions in men than in women, regardless of drug or cancer...
From the Journals
Checkpoint inhibitors get to patients quickly
Within about 4 months of FDA approval of PD-1 inhibitors, the majority of patients with melanoma, NSCLC, and RCC began receiving these agents.
From the Journals
Alternate 2:1 sunitinib schedule showed safety gains in renal cell carcinoma
The schedule missed its primary safety endpoint but led to fewer treatment discontinuations, dose reductions, and grade 3 toxicities than was...
Feature
Company discontinues phase 3 ADAPT for mRCC
A second interim analysis of the trial comparing Rocapuldencel-T in combination with sunitinib to sunitinib monotherapy led Argos Therapeutics to...
News
FDA approves immunotherapy combo for advanced RCC
Approvals were granted for nivolumab and ipilimumab in combination for the treatment of intermediate- or poor-risk, previously untreated advanced...
From the Journals
Do industry payments increase prescribing for some targeted therapies?
Some oncologists prescribing treatments for CML and RCC were more likely to prescribe a drug when they had received general payments from the drug...
Conference Coverage
Diabetes from checkpoint inhibitors probably means lifelong insulin
CHICAGO – In the largest case series to date, almost all patients remained on insulin at a median follow-up of 44 weeks, even after stopping ICIs...
From the Journals
Tivozanib after sorafenib promising in patients with advanced RCC
Median overall survival was 21.6 months for patients receiving tivozanib in a single-arm, phase 2 crossover study of patients previously...
From the Journals
Axitinib/avelumab combo shows preliminary efficacy in RCC
Hypertension was the most common adverse event related to the treatment.
From the Journals
Excellent prognosis for cystic RCC evaluated with radiologic threshold of greater than 50%
There was no evidence of tumor recurrence or metastasis from cRCC for both active surveillance and following surgery when evaluated with a...
From the Journals
Immunotherapy regimen influences inflammatory arthritis presentation
Variations in the clinical presentation of immunotherapy-induced inflammatory arthritis is partly explained by which treatment regimen is used to...